Redx Pharma Plc Shares Begin Trading on JP Jenkins Platform

As of May 1, 2024, Redx Pharma Plc, a clinical-stage biotechnology company, has its shares trading on the JP Jenkins share dealing platform. Redx Pharma, known for its focus on fibrotic diseases and cancer treatments, is located in Alderley Park, Macclesfield, England.

JP Jenkins is known for providing trading venues for shares of unlisted companies, facilitating transactions on a matched bargain basis. This allows shareholders and investors to trade shares during standard business hours through UK regulated stockbrokers.

Peter Collum, CFO of Redx Pharma, expressed satisfaction with the transition from AIM to JP Jenkins, noting it allows the company to pursue its corporate strategies more effectively while providing liquidity to shareholders. Meanwhile, Veronika Oswald, Commercial Director of JP Jenkins, highlighted the transition as a significant move towards enhancing investor accessibility and liquidity.